Journal article
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection
M Julsgaard, LA Christensen, PR Gibson, RB Gearry, J Fallingborg, CL Hvas, BM Bibby, N Uldbjerg, WR Connell, O Rosella, A Grosen, SJ Brown, J Kjeldsen, S Wildt, L Svenningsen, MP Sparrow, A Walsh, SJ Connor, G Radford-Smith, IC Lawrance Show all
Gastroenterology | W B SAUNDERS CO-ELSEVIER INC | Published : 2016
Abstract
Background & Aims Little is known about in utero exposure to and postnatal clearance of anti–tumor necrosis factor (anti-TNF) agents in neonates. We investigated the concentrations of adalimumab and infliximab in umbilical cord blood of newborns and rates of clearance after birth, and how these correlated with drug concentrations in mothers at birth and risk of infection during the first year of life. Methods We performed a prospective study of 80 pregnant women with inflammatory bowel diseases at tertiary hospitals in Denmark, Australia, and New Zealand from March 2012 through November 2014: 36 received adalimumab and 44 received infliximab; 39 received concomitant thiopurines during pregna..
View full abstractGrants
Funding Acknowledgements
The intra-uterine ExposuRe to Anti-tnf-alpha therapy (ERA) study was supported by unrestricted grants from the Health Research Fund of the Central Denmark Region, Colitis-Crohn Denmark, the A.P. Moeller Foundation of the Advancement of Medical Science, the Department of Gastroenterology at Monash University, and Alfred Hospital (Melbourne, Victoria, Australia). The external funders had no involvement in any aspect of the study or writing of the report.